# Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)

> **NCT03177239** · PHASE2 · UNKNOWN · sponsor: **Australian and New Zealand Urogenital and Prostate Cancer Trials Group** · enrollment: 85 (actual)

## Conditions studied

- Renal Cell Carcinoma
- Papillary Renal Cell Carcinoma Type 1
- Papillary Renal Cell Carcinoma Type 2
- Chromophobe Renal Cell Carcinoma
- Sarcomatoid Renal Cell Carcinoma
- Xp11 Translocation Carcinoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT03177239
- **Lead sponsor:** Australian and New Zealand Urogenital and Prostate Cancer Trials Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-10-19
- **Primary completion:** 2021-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2022-02-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03177239

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03177239, "Phase II Sequential Treatment Trial of Single Agent Nivolumab, Then Combination Ipilimumab + Nivolumab in Metastatic or Unresectable Non-Clear Cell Renal Cell Carcinoma (ANZUP1602)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03177239. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*